nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentazocine—EBP—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.00941	1	CbGdCrCtD
Pentazocine—Hypertension—Gliclazide—type 2 diabetes mellitus	0.00126	0.00171	CcSEcCtD
Pentazocine—Chills—Metformin—type 2 diabetes mellitus	0.00126	0.00171	CcSEcCtD
Pentazocine—Vision blurred—Orlistat—type 2 diabetes mellitus	0.00125	0.0017	CcSEcCtD
Pentazocine—Constipation—Bromocriptine—type 2 diabetes mellitus	0.00124	0.00169	CcSEcCtD
Pentazocine—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.00124	0.00169	CcSEcCtD
Pentazocine—Hypotension—Glyburide—type 2 diabetes mellitus	0.00124	0.00169	CcSEcCtD
Pentazocine—Nausea—Repaglinide—type 2 diabetes mellitus	0.00124	0.00168	CcSEcCtD
Pentazocine—Asthenia—Glipizide—type 2 diabetes mellitus	0.00124	0.00168	CcSEcCtD
Pentazocine—Tinnitus—Irbesartan—type 2 diabetes mellitus	0.00124	0.00168	CcSEcCtD
Pentazocine—Headache—Rosiglitazone—type 2 diabetes mellitus	0.00124	0.00168	CcSEcCtD
Pentazocine—Flushing—Irbesartan—type 2 diabetes mellitus	0.00123	0.00167	CcSEcCtD
Pentazocine—Pruritus—Glipizide—type 2 diabetes mellitus	0.00122	0.00166	CcSEcCtD
Pentazocine—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.00122	0.00165	CcSEcCtD
Pentazocine—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.00122	0.00165	CcSEcCtD
Pentazocine—Vertigo—Valsartan—type 2 diabetes mellitus	0.00121	0.00164	CcSEcCtD
Pentazocine—Syncope—Valsartan—type 2 diabetes mellitus	0.0012	0.00164	CcSEcCtD
Pentazocine—Confusional state—Gliclazide—type 2 diabetes mellitus	0.0012	0.00163	CcSEcCtD
Pentazocine—Dysgeusia—Metformin—type 2 diabetes mellitus	0.0012	0.00163	CcSEcCtD
Pentazocine—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.0012	0.00163	CcSEcCtD
Pentazocine—Paraesthesia—Glyburide—type 2 diabetes mellitus	0.00119	0.00162	CcSEcCtD
Pentazocine—Vertigo—Orlistat—type 2 diabetes mellitus	0.00119	0.00162	CcSEcCtD
Pentazocine—Chills—Irbesartan—type 2 diabetes mellitus	0.00119	0.00162	CcSEcCtD
Pentazocine—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.00119	0.00161	CcSEcCtD
Pentazocine—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.00119	0.00161	CcSEcCtD
Pentazocine—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.00118	0.00161	CcSEcCtD
Pentazocine—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.00118	0.00161	CcSEcCtD
Pentazocine—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.00118	0.0016	CcSEcCtD
Pentazocine—Loss of consciousness—Valsartan—type 2 diabetes mellitus	0.00118	0.0016	CcSEcCtD
Pentazocine—Erythema multiforme—Losartan—type 2 diabetes mellitus	0.00118	0.0016	CcSEcCtD
Pentazocine—Muscle spasms—Metformin—type 2 diabetes mellitus	0.00118	0.0016	CcSEcCtD
Pentazocine—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00117	0.00159	CcSEcCtD
Pentazocine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.00116	0.00158	CcSEcCtD
Pentazocine—Tinnitus—Losartan—type 2 diabetes mellitus	0.00116	0.00158	CcSEcCtD
Pentazocine—Flushing—Losartan—type 2 diabetes mellitus	0.00116	0.00157	CcSEcCtD
Pentazocine—Asthenia—Glimepiride—type 2 diabetes mellitus	0.00116	0.00157	CcSEcCtD
Pentazocine—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.00116	0.00157	CcSEcCtD
Pentazocine—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	0.00115	0.00157	CcSEcCtD
Pentazocine—Vision blurred—Metformin—type 2 diabetes mellitus	0.00115	0.00157	CcSEcCtD
Pentazocine—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.00115	0.00156	CcSEcCtD
Pentazocine—Tremor—Metformin—type 2 diabetes mellitus	0.00115	0.00156	CcSEcCtD
Pentazocine—Sweating—Ramipril—type 2 diabetes mellitus	0.00114	0.00155	CcSEcCtD
Pentazocine—Dizziness—Glipizide—type 2 diabetes mellitus	0.00114	0.00155	CcSEcCtD
Pentazocine—Pruritus—Glimepiride—type 2 diabetes mellitus	0.00114	0.00155	CcSEcCtD
Pentazocine—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.00113	0.00154	CcSEcCtD
Pentazocine—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.00113	0.00154	CcSEcCtD
Pentazocine—Dry mouth—Valsartan—type 2 diabetes mellitus	0.00112	0.00152	CcSEcCtD
Pentazocine—Hypotension—Gliclazide—type 2 diabetes mellitus	0.00111	0.00151	CcSEcCtD
Pentazocine—Agranulocytosis—Ramipril—type 2 diabetes mellitus	0.00111	0.00151	CcSEcCtD
Pentazocine—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.00111	0.00151	CcSEcCtD
Pentazocine—Dry mouth—Orlistat—type 2 diabetes mellitus	0.00111	0.0015	CcSEcCtD
Pentazocine—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.0011	0.0015	CcSEcCtD
Pentazocine—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.0011	0.00149	CcSEcCtD
Pentazocine—Vomiting—Glipizide—type 2 diabetes mellitus	0.0011	0.00149	CcSEcCtD
Pentazocine—Syncope—Metformin—type 2 diabetes mellitus	0.0011	0.00149	CcSEcCtD
Pentazocine—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.0011	0.00149	CcSEcCtD
Pentazocine—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.00109	0.00149	CcSEcCtD
Pentazocine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.00109	0.00149	CcSEcCtD
Pentazocine—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.00109	0.00148	CcSEcCtD
Pentazocine—Dermatitis—Glipizide—type 2 diabetes mellitus	0.00109	0.00148	CcSEcCtD
Pentazocine—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.00108	0.00147	CcSEcCtD
Pentazocine—Headache—Glipizide—type 2 diabetes mellitus	0.00108	0.00147	CcSEcCtD
Pentazocine—Tremor—Irbesartan—type 2 diabetes mellitus	0.00108	0.00147	CcSEcCtD
Pentazocine—Insomnia—Gliclazide—type 2 diabetes mellitus	0.00108	0.00147	CcSEcCtD
Pentazocine—Shock—Valsartan—type 2 diabetes mellitus	0.00108	0.00146	CcSEcCtD
Pentazocine—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.00108	0.00146	CcSEcCtD
Pentazocine—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.00107	0.00145	CcSEcCtD
Pentazocine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.00107	0.00145	CcSEcCtD
Pentazocine—Dysgeusia—Losartan—type 2 diabetes mellitus	0.00106	0.00144	CcSEcCtD
Pentazocine—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.00106	0.00144	CcSEcCtD
Pentazocine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.00106	0.00144	CcSEcCtD
Pentazocine—Agitation—Irbesartan—type 2 diabetes mellitus	0.00106	0.00144	CcSEcCtD
Pentazocine—Somnolence—Gliclazide—type 2 diabetes mellitus	0.00106	0.00144	CcSEcCtD
Pentazocine—Hypertension—Metformin—type 2 diabetes mellitus	0.00106	0.00143	CcSEcCtD
Pentazocine—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.00105	0.00142	CcSEcCtD
Pentazocine—Anorexia—Valsartan—type 2 diabetes mellitus	0.00104	0.00142	CcSEcCtD
Pentazocine—Muscle spasms—Losartan—type 2 diabetes mellitus	0.00104	0.00142	CcSEcCtD
Pentazocine—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.00104	0.00142	CcSEcCtD
Pentazocine—Vertigo—Irbesartan—type 2 diabetes mellitus	0.00104	0.00141	CcSEcCtD
Pentazocine—Headache—Pioglitazone—type 2 diabetes mellitus	0.00104	0.00141	CcSEcCtD
Pentazocine—Syncope—Irbesartan—type 2 diabetes mellitus	0.00104	0.00141	CcSEcCtD
Pentazocine—Visual impairment—Ramipril—type 2 diabetes mellitus	0.00103	0.0014	CcSEcCtD
Pentazocine—Nausea—Glipizide—type 2 diabetes mellitus	0.00103	0.00139	CcSEcCtD
Pentazocine—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00102	0.00139	CcSEcCtD
Pentazocine—Hypotension—Valsartan—type 2 diabetes mellitus	0.00102	0.00139	CcSEcCtD
Pentazocine—Vision blurred—Losartan—type 2 diabetes mellitus	0.00102	0.00139	CcSEcCtD
Pentazocine—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00102	0.00139	CcSEcCtD
Pentazocine—Constipation—Gliclazide—type 2 diabetes mellitus	0.00102	0.00139	CcSEcCtD
Pentazocine—Tremor—Losartan—type 2 diabetes mellitus	0.00102	0.00138	CcSEcCtD
Pentazocine—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.00101	0.00138	CcSEcCtD
Pentazocine—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.00101	0.00138	CcSEcCtD
Pentazocine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.00101	0.00137	CcSEcCtD
Pentazocine—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.00101	0.00137	CcSEcCtD
Pentazocine—Headache—Glimepiride—type 2 diabetes mellitus	0.00101	0.00137	CcSEcCtD
Pentazocine—Headache—Sitagliptin—type 2 diabetes mellitus	0.00101	0.00137	CcSEcCtD
Pentazocine—Agitation—Losartan—type 2 diabetes mellitus	0.000998	0.00136	CcSEcCtD
Pentazocine—Tinnitus—Ramipril—type 2 diabetes mellitus	0.000998	0.00135	CcSEcCtD
Pentazocine—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000997	0.00135	CcSEcCtD
Pentazocine—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000995	0.00135	CcSEcCtD
Pentazocine—Flushing—Ramipril—type 2 diabetes mellitus	0.000993	0.00135	CcSEcCtD
Pentazocine—Insomnia—Valsartan—type 2 diabetes mellitus	0.000991	0.00135	CcSEcCtD
Pentazocine—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000984	0.00134	CcSEcCtD
Pentazocine—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000983	0.00134	CcSEcCtD
Pentazocine—Shock—Metformin—type 2 diabetes mellitus	0.000982	0.00133	CcSEcCtD
Pentazocine—Insomnia—Orlistat—type 2 diabetes mellitus	0.00098	0.00133	CcSEcCtD
Pentazocine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000979	0.00133	CcSEcCtD
Pentazocine—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000977	0.00133	CcSEcCtD
Pentazocine—Vertigo—Losartan—type 2 diabetes mellitus	0.000976	0.00133	CcSEcCtD
Pentazocine—Somnolence—Valsartan—type 2 diabetes mellitus	0.000975	0.00132	CcSEcCtD
Pentazocine—Syncope—Losartan—type 2 diabetes mellitus	0.000974	0.00132	CcSEcCtD
Pentazocine—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000973	0.00132	CcSEcCtD
Pentazocine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000965	0.00131	CcSEcCtD
Pentazocine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000961	0.00131	CcSEcCtD
Pentazocine—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000961	0.00131	CcSEcCtD
Pentazocine—Nausea—Glimepiride—type 2 diabetes mellitus	0.000957	0.0013	CcSEcCtD
Pentazocine—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000955	0.0013	CcSEcCtD
Pentazocine—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000954	0.0013	CcSEcCtD
Pentazocine—Asthenia—Glyburide—type 2 diabetes mellitus	0.000953	0.00129	CcSEcCtD
Pentazocine—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000953	0.00129	CcSEcCtD
Pentazocine—Anorexia—Metformin—type 2 diabetes mellitus	0.000952	0.00129	CcSEcCtD
Pentazocine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000942	0.00128	CcSEcCtD
Pentazocine—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000942	0.00128	CcSEcCtD
Pentazocine—Pruritus—Glyburide—type 2 diabetes mellitus	0.00094	0.00128	CcSEcCtD
Pentazocine—Constipation—Valsartan—type 2 diabetes mellitus	0.000937	0.00127	CcSEcCtD
Pentazocine—Hypotension—Metformin—type 2 diabetes mellitus	0.000933	0.00127	CcSEcCtD
Pentazocine—Shock—Irbesartan—type 2 diabetes mellitus	0.000927	0.00126	CcSEcCtD
Pentazocine—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000924	0.00126	CcSEcCtD
Pentazocine—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000919	0.00125	CcSEcCtD
Pentazocine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000916	0.00124	CcSEcCtD
Pentazocine—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000912	0.00124	CcSEcCtD
Pentazocine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000911	0.00124	CcSEcCtD
Pentazocine—Headache—Bromocriptine—type 2 diabetes mellitus	0.000911	0.00124	CcSEcCtD
Pentazocine—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000909	0.00123	CcSEcCtD
Pentazocine—Dry mouth—Losartan—type 2 diabetes mellitus	0.000904	0.00123	CcSEcCtD
Pentazocine—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000898	0.00122	CcSEcCtD
Pentazocine—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000896	0.00122	CcSEcCtD
Pentazocine—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000896	0.00122	CcSEcCtD
Pentazocine—Confusional state—Losartan—type 2 diabetes mellitus	0.000894	0.00121	CcSEcCtD
Pentazocine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000893	0.00121	CcSEcCtD
Pentazocine—Dyspnoea—Metformin—type 2 diabetes mellitus	0.00089	0.00121	CcSEcCtD
Pentazocine—Somnolence—Metformin—type 2 diabetes mellitus	0.000887	0.00121	CcSEcCtD
Pentazocine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000887	0.0012	CcSEcCtD
Pentazocine—Hypotension—Irbesartan—type 2 diabetes mellitus	0.00088	0.0012	CcSEcCtD
Pentazocine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000879	0.00119	CcSEcCtD
Pentazocine—Tremor—Ramipril—type 2 diabetes mellitus	0.000873	0.00119	CcSEcCtD
Pentazocine—Shock—Losartan—type 2 diabetes mellitus	0.000872	0.00118	CcSEcCtD
Pentazocine—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000868	0.00118	CcSEcCtD
Pentazocine—Tachycardia—Losartan—type 2 diabetes mellitus	0.000865	0.00118	CcSEcCtD
Pentazocine—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000863	0.00117	CcSEcCtD
Pentazocine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000857	0.00116	CcSEcCtD
Pentazocine—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000856	0.00116	CcSEcCtD
Pentazocine—Agitation—Ramipril—type 2 diabetes mellitus	0.000856	0.00116	CcSEcCtD
Pentazocine—Constipation—Metformin—type 2 diabetes mellitus	0.000854	0.00116	CcSEcCtD
Pentazocine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000846	0.00115	CcSEcCtD
Pentazocine—Anorexia—Losartan—type 2 diabetes mellitus	0.000845	0.00115	CcSEcCtD
Pentazocine—Vomiting—Glyburide—type 2 diabetes mellitus	0.000845	0.00115	CcSEcCtD
Pentazocine—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000844	0.00115	CcSEcCtD
Pentazocine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.00084	0.00114	CcSEcCtD
Pentazocine—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000837	0.00114	CcSEcCtD
Pentazocine—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000837	0.00114	CcSEcCtD
Pentazocine—Vertigo—Ramipril—type 2 diabetes mellitus	0.000837	0.00114	CcSEcCtD
Pentazocine—Syncope—Ramipril—type 2 diabetes mellitus	0.000835	0.00113	CcSEcCtD
Pentazocine—Headache—Glyburide—type 2 diabetes mellitus	0.000832	0.00113	CcSEcCtD
Pentazocine—Hypotension—Losartan—type 2 diabetes mellitus	0.000828	0.00113	CcSEcCtD
Pentazocine—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000823	0.00112	CcSEcCtD
Pentazocine—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000819	0.00111	CcSEcCtD
Pentazocine—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000819	0.00111	CcSEcCtD
Pentazocine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000816	0.00111	CcSEcCtD
Pentazocine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000808	0.0011	CcSEcCtD
Pentazocine—Constipation—Irbesartan—type 2 diabetes mellitus	0.000806	0.00109	CcSEcCtD
Pentazocine—Insomnia—Losartan—type 2 diabetes mellitus	0.000802	0.00109	CcSEcCtD
Pentazocine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000798	0.00108	CcSEcCtD
Pentazocine—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000796	0.00108	CcSEcCtD
Pentazocine—Dyspnoea—Losartan—type 2 diabetes mellitus	0.00079	0.00107	CcSEcCtD
Pentazocine—Nausea—Glyburide—type 2 diabetes mellitus	0.000789	0.00107	CcSEcCtD
Pentazocine—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000789	0.00107	CcSEcCtD
Pentazocine—Somnolence—Losartan—type 2 diabetes mellitus	0.000788	0.00107	CcSEcCtD
Pentazocine—Asthenia—Valsartan—type 2 diabetes mellitus	0.000787	0.00107	CcSEcCtD
Pentazocine—Asthenia—Orlistat—type 2 diabetes mellitus	0.000777	0.00106	CcSEcCtD
Pentazocine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000776	0.00105	CcSEcCtD
Pentazocine—Pruritus—Valsartan—type 2 diabetes mellitus	0.000776	0.00105	CcSEcCtD
Pentazocine—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000776	0.00105	CcSEcCtD
Pentazocine—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000771	0.00105	CcSEcCtD
Pentazocine—Confusional state—Ramipril—type 2 diabetes mellitus	0.000767	0.00104	CcSEcCtD
Pentazocine—Pruritus—Orlistat—type 2 diabetes mellitus	0.000766	0.00104	CcSEcCtD
Pentazocine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.00076	0.00103	CcSEcCtD
Pentazocine—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000759	0.00103	CcSEcCtD
Pentazocine—Constipation—Losartan—type 2 diabetes mellitus	0.000758	0.00103	CcSEcCtD
Pentazocine—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000752	0.00102	CcSEcCtD
Pentazocine—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.00075	0.00102	CcSEcCtD
Pentazocine—Shock—Ramipril—type 2 diabetes mellitus	0.000748	0.00102	CcSEcCtD
Pentazocine—Headache—Gliclazide—type 2 diabetes mellitus	0.000747	0.00102	CcSEcCtD
Pentazocine—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000742	0.00101	CcSEcCtD
Pentazocine—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000741	0.00101	CcSEcCtD
Pentazocine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000735	0.000998	CcSEcCtD
Pentazocine—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000731	0.000992	CcSEcCtD
Pentazocine—Dizziness—Valsartan—type 2 diabetes mellitus	0.000725	0.000984	CcSEcCtD
Pentazocine—Anorexia—Ramipril—type 2 diabetes mellitus	0.000725	0.000984	CcSEcCtD
Pentazocine—Dizziness—Orlistat—type 2 diabetes mellitus	0.000716	0.000973	CcSEcCtD
Pentazocine—Asthenia—Metformin—type 2 diabetes mellitus	0.000716	0.000973	CcSEcCtD
Pentazocine—Hypotension—Ramipril—type 2 diabetes mellitus	0.00071	0.000965	CcSEcCtD
Pentazocine—Nausea—Gliclazide—type 2 diabetes mellitus	0.000709	0.000962	CcSEcCtD
Pentazocine—Pruritus—Metformin—type 2 diabetes mellitus	0.000706	0.000959	CcSEcCtD
Pentazocine—Vomiting—Valsartan—type 2 diabetes mellitus	0.000697	0.000947	CcSEcCtD
Pentazocine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000694	0.000943	CcSEcCtD
Pentazocine—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000691	0.000938	CcSEcCtD
Pentazocine—Vomiting—Orlistat—type 2 diabetes mellitus	0.000689	0.000935	CcSEcCtD
Pentazocine—Insomnia—Ramipril—type 2 diabetes mellitus	0.000688	0.000934	CcSEcCtD
Pentazocine—Headache—Valsartan—type 2 diabetes mellitus	0.000687	0.000933	CcSEcCtD
Pentazocine—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000683	0.000928	CcSEcCtD
Pentazocine—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000683	0.000927	CcSEcCtD
Pentazocine—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000682	0.000927	CcSEcCtD
Pentazocine—Headache—Orlistat—type 2 diabetes mellitus	0.000679	0.000922	CcSEcCtD
Pentazocine—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000678	0.00092	CcSEcCtD
Pentazocine—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000676	0.000918	CcSEcCtD
Pentazocine—Somnolence—Ramipril—type 2 diabetes mellitus	0.000676	0.000918	CcSEcCtD
Pentazocine—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000667	0.000905	CcSEcCtD
Pentazocine—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000661	0.000897	CcSEcCtD
Pentazocine—Dizziness—Metformin—type 2 diabetes mellitus	0.00066	0.000896	CcSEcCtD
Pentazocine—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000653	0.000887	CcSEcCtD
Pentazocine—Nausea—Valsartan—type 2 diabetes mellitus	0.000651	0.000884	CcSEcCtD
Pentazocine—Constipation—Ramipril—type 2 diabetes mellitus	0.00065	0.000883	CcSEcCtD
Pentazocine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000645	0.000875	CcSEcCtD
Pentazocine—Nausea—Orlistat—type 2 diabetes mellitus	0.000643	0.000874	CcSEcCtD
Pentazocine—Asthenia—Losartan—type 2 diabetes mellitus	0.000636	0.000864	CcSEcCtD
Pentazocine—Vomiting—Metformin—type 2 diabetes mellitus	0.000635	0.000862	CcSEcCtD
Pentazocine—Dermatitis—Metformin—type 2 diabetes mellitus	0.000629	0.000854	CcSEcCtD
Pentazocine—Pruritus—Losartan—type 2 diabetes mellitus	0.000627	0.000852	CcSEcCtD
Pentazocine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000626	0.000851	CcSEcCtD
Pentazocine—Headache—Metformin—type 2 diabetes mellitus	0.000625	0.000849	CcSEcCtD
Pentazocine—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000623	0.000846	CcSEcCtD
Pentazocine—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000607	0.000824	CcSEcCtD
Pentazocine—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000599	0.000813	CcSEcCtD
Pentazocine—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000593	0.000806	CcSEcCtD
Pentazocine—Nausea—Metformin—type 2 diabetes mellitus	0.000593	0.000805	CcSEcCtD
Pentazocine—Headache—Irbesartan—type 2 diabetes mellitus	0.00059	0.000801	CcSEcCtD
Pentazocine—Dizziness—Losartan—type 2 diabetes mellitus	0.000586	0.000796	CcSEcCtD
Pentazocine—Vomiting—Losartan—type 2 diabetes mellitus	0.000564	0.000766	CcSEcCtD
Pentazocine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.00056	0.000761	CcSEcCtD
Pentazocine—Nausea—Irbesartan—type 2 diabetes mellitus	0.00056	0.00076	CcSEcCtD
Pentazocine—Dermatitis—Losartan—type 2 diabetes mellitus	0.000558	0.000758	CcSEcCtD
Pentazocine—Headache—Losartan—type 2 diabetes mellitus	0.000555	0.000754	CcSEcCtD
Pentazocine—Asthenia—Ramipril—type 2 diabetes mellitus	0.000545	0.000741	CcSEcCtD
Pentazocine—Pruritus—Ramipril—type 2 diabetes mellitus	0.000538	0.00073	CcSEcCtD
Pentazocine—Nausea—Losartan—type 2 diabetes mellitus	0.000527	0.000715	CcSEcCtD
Pentazocine—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.00052	0.000706	CcSEcCtD
Pentazocine—Dizziness—Ramipril—type 2 diabetes mellitus	0.000503	0.000683	CcSEcCtD
Pentazocine—Vomiting—Ramipril—type 2 diabetes mellitus	0.000483	0.000656	CcSEcCtD
Pentazocine—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000479	0.00065	CcSEcCtD
Pentazocine—Headache—Ramipril—type 2 diabetes mellitus	0.000476	0.000647	CcSEcCtD
Pentazocine—Nausea—Ramipril—type 2 diabetes mellitus	0.000452	0.000613	CcSEcCtD
Pentazocine—OPRD1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	0.00011	0.000431	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	0.000109	0.000431	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CCKAR—type 2 diabetes mellitus	0.000109	0.00043	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ADRB3—type 2 diabetes mellitus	0.000109	0.000429	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	0.000109	0.000429	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	0.000108	0.000426	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	0.000107	0.000423	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—EDN1—type 2 diabetes mellitus	0.000105	0.000415	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CRHR1—type 2 diabetes mellitus	0.000105	0.000414	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—C3—type 2 diabetes mellitus	0.000105	0.000413	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	0.000105	0.000411	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	0.000104	0.00041	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	0.000104	0.000408	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—AVP—type 2 diabetes mellitus	0.000103	0.000406	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	0.000102	0.000399	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—C3—type 2 diabetes mellitus	0.000101	0.000399	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	0.000101	0.000398	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	0.000101	0.000398	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	0.0001	0.000394	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—AGT—type 2 diabetes mellitus	9.98e-05	0.000393	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	9.9e-05	0.00039	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	9.85e-05	0.000388	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IAPP—type 2 diabetes mellitus	9.84e-05	0.000387	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	9.81e-05	0.000386	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	9.81e-05	0.000386	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CYBA—type 2 diabetes mellitus	9.81e-05	0.000386	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—INSR—type 2 diabetes mellitus	9.78e-05	0.000385	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	9.72e-05	0.000382	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	9.64e-05	0.000379	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—AGT—type 2 diabetes mellitus	9.64e-05	0.000379	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—SPRY2—type 2 diabetes mellitus	9.64e-05	0.000379	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	9.64e-05	0.000379	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	9.61e-05	0.000378	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—GHRL—type 2 diabetes mellitus	9.6e-05	0.000378	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PLAT—type 2 diabetes mellitus	9.6e-05	0.000378	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	9.6e-05	0.000378	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	9.55e-05	0.000376	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—GNB3—type 2 diabetes mellitus	9.5e-05	0.000374	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CALCA—type 2 diabetes mellitus	9.48e-05	0.000373	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	9.43e-05	0.000371	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—GLP1R—type 2 diabetes mellitus	9.39e-05	0.000369	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—RBP4—type 2 diabetes mellitus	9.39e-05	0.000369	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—AVP—type 2 diabetes mellitus	9.37e-05	0.000368	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—MMP3—type 2 diabetes mellitus	9.37e-05	0.000368	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	9.32e-05	0.000367	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CCKAR—type 2 diabetes mellitus	9.24e-05	0.000363	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	9.22e-05	0.000363	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—C3—type 2 diabetes mellitus	9.21e-05	0.000362	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	9.15e-05	0.00036	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	8.93e-05	0.000351	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—EDN1—type 2 diabetes mellitus	8.91e-05	0.00035	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	8.9e-05	0.00035	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	8.89e-05	0.00035	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	8.88e-05	0.000349	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	8.88e-05	0.000349	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—GCG—type 2 diabetes mellitus	8.78e-05	0.000345	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	8.78e-05	0.000345	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	8.77e-05	0.000345	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—AGT—type 2 diabetes mellitus	8.75e-05	0.000344	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	8.64e-05	0.00034	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	8.64e-05	0.00034	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	8.61e-05	0.000339	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	8.6e-05	0.000338	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CYBA—type 2 diabetes mellitus	8.6e-05	0.000338	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—C3—type 2 diabetes mellitus	8.57e-05	0.000337	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	8.46e-05	0.000333	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	8.46e-05	0.000333	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—GHRL—type 2 diabetes mellitus	8.42e-05	0.000331	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PLAT—type 2 diabetes mellitus	8.42e-05	0.000331	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	8.37e-05	0.000329	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IAPP—type 2 diabetes mellitus	8.32e-05	0.000327	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CALCA—type 2 diabetes mellitus	8.32e-05	0.000327	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—INSR—type 2 diabetes mellitus	8.27e-05	0.000325	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	8.22e-05	0.000323	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—AGT—type 2 diabetes mellitus	8.14e-05	0.00032	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	8.12e-05	0.000319	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	8.11e-05	0.000319	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	8.09e-05	0.000318	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	8.07e-05	0.000318	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	8.07e-05	0.000318	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	8.07e-05	0.000317	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	7.97e-05	0.000313	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	7.83e-05	0.000308	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	7.8e-05	0.000307	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—C3—type 2 diabetes mellitus	7.78e-05	0.000306	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	7.73e-05	0.000304	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	7.7e-05	0.000303	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—GCG—type 2 diabetes mellitus	7.7e-05	0.000303	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	7.64e-05	0.000301	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	7.58e-05	0.000298	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—GNB3—type 2 diabetes mellitus	7.57e-05	0.000298	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	7.55e-05	0.000297	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	7.53e-05	0.000296	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	7.51e-05	0.000295	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	7.51e-05	0.000295	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—AVP—type 2 diabetes mellitus	7.47e-05	0.000294	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—MMP3—type 2 diabetes mellitus	7.47e-05	0.000294	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IGF2—type 2 diabetes mellitus	7.43e-05	0.000292	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	7.4e-05	0.000291	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—AGT—type 2 diabetes mellitus	7.4e-05	0.000291	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	7.33e-05	0.000288	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	7.3e-05	0.000287	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	7.27e-05	0.000286	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CYBA—type 2 diabetes mellitus	7.27e-05	0.000286	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—APOB—type 2 diabetes mellitus	7.22e-05	0.000284	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	7.21e-05	0.000283	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	7.19e-05	0.000283	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	7.15e-05	0.000281	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—GHRL—type 2 diabetes mellitus	7.12e-05	0.00028	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PLAT—type 2 diabetes mellitus	7.12e-05	0.00028	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—EDN1—type 2 diabetes mellitus	7.1e-05	0.000279	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	7.08e-05	0.000278	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	7.07e-05	0.000278	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CALCA—type 2 diabetes mellitus	7.03e-05	0.000276	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—LPL—type 2 diabetes mellitus	6.89e-05	0.000271	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	6.83e-05	0.000269	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	6.75e-05	0.000265	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	6.7e-05	0.000264	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—GNB3—type 2 diabetes mellitus	6.64e-05	0.000261	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	6.62e-05	0.00026	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	6.59e-05	0.000259	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—AVP—type 2 diabetes mellitus	6.55e-05	0.000258	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—MMP3—type 2 diabetes mellitus	6.55e-05	0.000258	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IGF2—type 2 diabetes mellitus	6.52e-05	0.000256	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—GCG—type 2 diabetes mellitus	6.51e-05	0.000256	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	6.51e-05	0.000256	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	6.49e-05	0.000255	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.47e-05	0.000254	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	6.42e-05	0.000253	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	6.4e-05	0.000252	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	6.38e-05	0.000251	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.35e-05	0.00025	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—APOB—type 2 diabetes mellitus	6.33e-05	0.000249	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	6.3e-05	0.000248	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—EDN1—type 2 diabetes mellitus	6.23e-05	0.000245	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—C3—type 2 diabetes mellitus	6.21e-05	0.000244	CbGpPWpGaD
Pentazocine—EBP—Metabolism—AKT1—type 2 diabetes mellitus	6.09e-05	0.00024	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	6.09e-05	0.00024	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—LPL—type 2 diabetes mellitus	6.04e-05	0.000238	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	5.98e-05	0.000235	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	5.98e-05	0.000235	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.92e-05	0.000233	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.92e-05	0.000233	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.9e-05	0.000232	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—AGT—type 2 diabetes mellitus	5.9e-05	0.000232	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.8e-05	0.000228	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—APOE—type 2 diabetes mellitus	5.78e-05	0.000227	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—LEP—type 2 diabetes mellitus	5.78e-05	0.000227	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.71e-05	0.000225	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.67e-05	0.000223	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.66e-05	0.000223	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.61e-05	0.000221	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.57e-05	0.000219	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—AVP—type 2 diabetes mellitus	5.53e-05	0.000218	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.53e-05	0.000218	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.51e-05	0.000217	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.49e-05	0.000216	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.45e-05	0.000214	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—C3—type 2 diabetes mellitus	5.44e-05	0.000214	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.43e-05	0.000214	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—APOB—type 2 diabetes mellitus	5.35e-05	0.00021	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.33e-05	0.00021	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.26e-05	0.000207	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.19e-05	0.000204	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.18e-05	0.000204	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—AGT—type 2 diabetes mellitus	5.17e-05	0.000203	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.15e-05	0.000203	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	5.11e-05	0.000201	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.08e-05	0.0002	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—APOE—type 2 diabetes mellitus	5.07e-05	0.000199	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—LEP—type 2 diabetes mellitus	5.07e-05	0.000199	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.01e-05	0.000197	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5e-05	0.000197	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—INS—type 2 diabetes mellitus	4.93e-05	0.000194	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.86e-05	0.000191	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.79e-05	0.000188	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.78e-05	0.000188	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.77e-05	0.000188	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.77e-05	0.000188	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.75e-05	0.000187	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.71e-05	0.000185	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—C3—type 2 diabetes mellitus	4.6e-05	0.000181	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.53e-05	0.000178	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.52e-05	0.000178	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.39e-05	0.000172	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.37e-05	0.000172	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	4.37e-05	0.000172	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.33e-05	0.00017	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.33e-05	0.00017	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—INS—type 2 diabetes mellitus	4.33e-05	0.00017	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.3e-05	0.000169	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	4.28e-05	0.000168	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	4.28e-05	0.000168	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.26e-05	0.000167	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.23e-05	0.000166	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.19e-05	0.000165	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.18e-05	0.000165	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.16e-05	0.000164	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—RELA—type 2 diabetes mellitus	4.07e-05	0.00016	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.04e-05	0.000159	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.97e-05	0.000156	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.82e-05	0.00015	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.79e-05	0.000149	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.79e-05	0.000149	CbGpPWpGaD
Pentazocine—OPRD1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.71e-05	0.000146	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.67e-05	0.000145	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—INS—type 2 diabetes mellitus	3.66e-05	0.000144	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.65e-05	0.000144	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.6e-05	0.000142	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—RELA—type 2 diabetes mellitus	3.57e-05	0.000141	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.54e-05	0.000139	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.53e-05	0.000139	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.52e-05	0.000138	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.47e-05	0.000137	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.44e-05	0.000135	CbGpPWpGaD
Pentazocine—OPRD1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.37e-05	0.000132	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.36e-05	0.000132	CbGpPWpGaD
Pentazocine—OPRK1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.25e-05	0.000128	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.22e-05	0.000127	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.21e-05	0.000126	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.21e-05	0.000126	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	3.2e-05	0.000126	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.2e-05	0.000126	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.12e-05	0.000123	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.04e-05	0.00012	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	3.02e-05	0.000119	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.01e-05	0.000118	CbGpPWpGaD
Pentazocine—OPRK1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.95e-05	0.000116	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.86e-05	0.000113	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.81e-05	0.00011	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.81e-05	0.00011	CbGpPWpGaD
Pentazocine—OPRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.75e-05	0.000108	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.73e-05	0.000108	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.72e-05	0.000107	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.71e-05	0.000106	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.57e-05	0.000101	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.55e-05	0.0001	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.51e-05	9.87e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.5e-05	9.82e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.46e-05	9.68e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.37e-05	9.33e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.31e-05	9.09e-05	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.16e-05	8.48e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.12e-05	8.34e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.08e-05	8.18e-05	CbGpPWpGaD
Pentazocine—OPRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.99e-05	7.83e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.89e-05	7.44e-05	CbGpPWpGaD
Pentazocine—OPRK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.74e-05	6.86e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.6e-05	6.29e-05	CbGpPWpGaD
Pentazocine—OPRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.47e-05	5.8e-05	CbGpPWpGaD
